Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lenzilumab, an antibody targeting GM-CSF.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ravagalimab, an antibody targeting CD40.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vatelizumab, an antibody targeting Integrin α2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mavrilimumab, an antibody targeting GM-CSF receptor α.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Pemivibart, an antibody targeting SARS-CoV-2 spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sotrovimab, an antibody targeting SARS-CoV-2 spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Cilgavimab, an antibody targeting SARS-CoV-2 spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tixagevimab, an antibody targeting SARS-CoV-2 spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Bamlanivimab, an antibody targeting SARS-CoV-2 spike.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Eptinezumab, an antibody targeting CGRP.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erenumab, an antibody targeting CGRP receptor.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Galcanezumab, an antibody targeting CGRP.